Cd247 as a biomarker for assessing the effect of chemotherapeutic and biological drugs
AssigneeYissum Research Development Company of the Hebrew University of Jerusalem
InventorsMichal Baniyash, Julia Kanterman, Moshe Sade-Feldman, Eliran Ish-Shalom
Life of this patent
Estimating the term…
Abstract
The invention relates to methods, kits and compositions using CD247 as a biomarker for assessing the efficacy and selecting an appropriate therapy such as chemotherapeutic, biological therapy or combined therapy for treating a subject suffering from a pathologic disorder that leads to a chronic-inflammatory condition.
Claims27
A method for determining the efficacy of a treatment with a therapeutic agent on a subject suffering from a chronic inflammatory condition, wherein said therapeutic agent is at least one chemotherapeutic agent, at least one immunotherapeutic agent or any combination thereof, said method comprises the steps of:
- a. determining the level of expression of T cell antigen receptor (TCR) ζ chain (CD247) in at least one biological sample of said subject, to obtain an expression value, said sample is obtained after and during the initiation of said treatment;
- b. determining if the expression value obtained in step (a) is any one of, positive or negative with respect to a predetermined standard expression value or to an expression value of CD247 in a control sample;
- Wherein a positive expression value of said CD247 indicates that said subject responds to said treatment.
A composition comprising:
- a. detecting molecules specific for determining the level of expression of CD247 in a biological sample;
- and optionally
- b. detecting molecules specific for determining the level of expression of at least one reference control in a biological sample;
- said detecting molecules of (a) and (b) are attached to a solid support.
A kit comprising:
- (a) detecting molecules specific for determining the level of expression of CD247 in a biological sample and optionally detecting molecules specific for at least one reference control;
- and optionally at least one of:
- (b) pre-determined calibration curve providing at least one of standard expression values of CD247 and standard values determined for the rate of change in the CD247 expression in response to said treatment;
- (c) at least one control sample.
Dependencies are inferred from the claim text.